Literature DB >> 3480221

The effect of age on the pharmacokinetics of enoxacin.

B R Dobbs1, L R Gazeley, A J Campbell, I R Edwards.   

Abstract

We have studied the pharmacokinetics of enoxacin in two groups of subjects, 10 young (18-45 years) and 10 elderly adults (greater than 65 years) after a single oral dose of enoxacin (600 mg). Enoxacin was absorbed rapidly, peak plasma concentrations being reached within two hours in both groups. However, the peak plasma concentration of enoxacin was significantly higher in the elderly than in the young adults. The area under the concentration-time curve extrapolated to infinity was also significantly greater in the elderly compared with the young subjects, and the apparent renal clearance was significantly less in the elderly than in the young adults. Consequently, the urinary elimination of unchanged enoxacin was significantly reduced in the elderly. The apparent volume of distribution in the elderly was significantly less than in the young adults. The elimination half-time of enoxacin was similar in the two groups.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3480221     DOI: 10.1007/BF00610390

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

Review 1.  Aging and drug disposition: an update.

Authors:  D L Schmucker
Journal:  Pharmacol Rev       Date:  1985-06       Impact factor: 25.468

Review 2.  Drug therapy in the elderly.

Authors:  P C Ho; E J Triggs
Journal:  Aust N Z J Med       Date:  1984-04

3.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

4.  Pharmacokinetics in the elderly.

Authors:  M Rinetti; R Cerutti; M Cisternino; L Colombi Zinelli
Journal:  Int J Clin Pharmacol Res       Date:  1984

5.  Nomogram for estimating creatinine clearance.

Authors:  T D Bjornsson; D M Cocchetto; F X McGowan; C P Verghese; F Sedor
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

6.  Enoxacin treatment of urinary tract infections.

Authors:  M G Thomas; R B Ellis-Pegler
Journal:  J Antimicrob Chemother       Date:  1985-06       Impact factor: 5.790

7.  In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.

Authors:  R Wise; J M Andrews; G Danks
Journal:  J Antimicrob Chemother       Date:  1984-03       Impact factor: 5.790

8.  Enoxacin for the treatment of urinary tract infection.

Authors:  R R Bailey; B A Peddie
Journal:  N Z Med J       Date:  1985-04-24

9.  Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens.

Authors:  J R Carlson; S A Thornton; H L DuPont; A H West; J J Mathewson
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

10.  In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria.

Authors:  J T Rudrik; S J Cavalieri; E M Britt
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

View more
  13 in total

Review 1.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

Review 2.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 3.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Quinolones in the aged.

Authors:  L E Nicolle
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects.

Authors:  R M Stroshane; M H Silverman; R Sauerschell; R R Brown; A W Boddy; J A Cook
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.

Authors:  C R Marchbanks; D J Mikolich; K H Mayer; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 7.  Quinolone disposition in the elderly. Practical implications.

Authors:  I Nilsson-Ehle; B Ljungberg
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

Review 8.  Quinolones in the elderly.

Authors:  T Bergan
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 9.  Pharmacokinetics of temafloxacin after multiple oral administration.

Authors:  G R Granneman
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

10.  Pharmacokinetics of temafloxacin in patients with liver impairment.

Authors:  G R Granneman; G Mahr; C Locke; P Nickel; W Kirch; W Fabian; M Kinzig; K G Naber; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.